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Prostate cancer is the most common non-cutaneous neoplasm in the male population worldwide. It is typically
diagnosed in its early stages, and the disease exhibits a relatively indolent course in most patients. Despite the
curability of localized disease with prostatectomy and radiation therapy, some patients develop metastatic disease
and die. Although androgen deprivation is present in the majority of patients with metastatic prostate cancer, a state
of androgen resistance eventually develops. Castration-resistant prostate cancer, defined when there is progression of
disease despite low levels of testosterone, requires specialized care, and improved communication between medical
and urologic oncologists has been identified as a key component in delivering effective therapy. Despite being
considered a chemoresistant tumor in the past, the use of a prostate-specific antigen has paved the way for a new
generation of trials for castration-resistant prostate cancer. Docetaxel is a life-prolonging chemotherapy that has been
established as the standard first-line agent in two phase III clinical trials. Cabazitaxel, a novel taxane with activity in
cancer models resistant to paclitaxel and docetaxel, is the only agent that has been compared to a chemotherapy
control in a phase III clinical trial as a second-line therapy; it was found to prolong the overall survival of patients with
castration-resistant prostate cancer previously treated with docetaxel when compared to mitoxantrone. Other agents
used in this setting include abiraterone and sipuleucel-T, and novel therapies are continually being investigated in an
attempt to improve the outcome for patients with castration-resistant prostate cancer.
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INTRODUCTION
Prostate cancer is the most common non-cutaneous
neoplasm in the male population worldwide (1). The vast
majority of cases are diagnosed in the early stages (2), and the
disease exhibits a relatively indolent course in most patients
(3). In the United States, prostate cancer remains the most
common malignancy in men (2), despite the recent trend of
decreasing mortality from the disease (4). Likely as a result of
the early diagnosis through prostate-specific antigen (PSA)
testing, the clinical behavior of prostate cancer, and the age of
patients with this disease, there is a large difference between
incidence and mortality rates from prostate cancer in the
United States and Europe (2,5). Recently, prostate cancer has
become the most common cancer in Brazil, surpassing breast
cancer with an estimated 52,000 new cases each year (6).
Despite the indolent course of the disease and the
curability of localized disease with prostatectomy and
radiation therapy, some patients develop metastatic disease,
frequently involving the bones and other organs (7). Once
metastatic disease is diagnosed, the likelihood of dying from
prostate cancer surpasses death from other causes (8). For
these patients, treatment is performed with a palliative
intent, often involving androgen deprivation through
pharmacological or surgical orchiectomy. As a general rule,
androgen deprivation is present in 80% to 90% of patients
with metastatic prostate cancer. These patients have a
median progression-free survival (PFS) ranging from 12 to
30 months after treatment is initiated (9,10). However, a
state of androgen independency eventually emerges, his-
torically leading to a median overall survival (OS) of only 8
to 16 months from the time of its appearance (9,10). The
terms ‘androgen-independent,’ ‘hormone-refractory’, and
‘castration-resistant’ have been used interchangeably over
the years – not without some controversy (11) – to denote
the progression of disease despite castration levels of
testosterone (12). However, many recent studies and guide-
lines in metastatic disease have used the term castration-
resistant prostate cancer (CRPC) (13-16), which will be used
in the following review, based on the available therapeutic
modalities for patients whose disease progresses after the
use of standard hormone therapy.
DEFINING THE CASTRATION-RESISTANT STATE
Although most patients with metastatic prostate cancer
initially respond to androgen deprivation due to testoster-
one dependence in prostate cancer cells, and despite the fact
the secondary hormonal manipulations are active in some
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patients (17), prostate tumor cells eventually acquire the
capacity to survive and proliferate in an androgen-depleted
environment (7,18). Mechanisms that underlie the transition
from an androgen-sensitive to an androgen-resistant phe-
notype have been elucidated to some extent, and a variety of
cellular pathways are implicated in this phenomenon
(7,9,18-20). As a result, androgen-receptor mutations and
alterations in the androgen-signaling cascade are considered
to be responsible for the androgen-withdrawal response
that is observed in a minority of patients being treated with
antiandrogens (21).
In clinical practice, it is important to identify the patients
with metastatic prostate cancer that require treatment as
opposed to those whose disease is only manifested by a
rising serum PSA level (22). Likewise, it is important to
determine when an initially sensitive disease is no longer
responsive to androgen deprivation, and improved com-
munication between medical and urologic oncologists has
been identified as a key component in achieving this goal
(23). There is anecdotal evidence that many patients
continue to receive hormone therapy, despite the failure of
previous treatments, before being referred to a medical
oncologist. For practical purposes, it is useful to consider
patients as having progressive CRPC if their disease
progresses during androgen-deprivation therapy, including
the withdrawal of antiandrogens, and if at least 4-8 weeks
have elapsed after the withdrawal of antiandrogens (24,25)
The progression can be confirmed by a PSA elevation alone,
a bone scan with measurable disease, or clinical progression
(symptomatic progression). It should be noted that patients
with CRPC may benefit from continued androgen depriva-
tion, as androgen-sensitive clones are thought to play a role
in disease progression after discontinuing hormone therapy
(18).
FIRST-LINE TREATMENT OF CRPC
Historical development of and assessment of
response to chemotherapy
Until the late 1980s, prostate cancer was considered a
chemoresistant tumor (26). Several authors noted that the
response rates to the available agents were typically low but
also varied widely in different studies (26-28). In addition,
authors postulated that the documentation of responses in
prostate cancer was complicated by a lack of established
criteria to assess the effects of the drugs, as nearly 80% of
patients with CRPC have no measurable soft-tissue lesions
(29). Thus, the response rates could only be determined in
the minority of patients with measurable disease before the
PSA era. In the early 1990s, PSA became widely available
and was used in clinical trials as a measure of response
(7,30). In 1999, a consensus conference suggested that a
decline in PSA of at least 50% could represent a partial
response in clinical trials as long as there was confirmation
at least four weeks later and no clinical or radiographic
evidence of disease progression (31). The use of PSA has
allowed for a new generation of trials of CRPC treatments,
and PSA responses have been used as surrogates for
objective responses in this setting for early drug develop-
ment (31). However, the PSA response has not been
validated as a surrogate for OS in androgen-sensitive
disease or in CRPC, and OS remains the most relevant
endpoint in phase III clinical trials (32,33). In addition, other
time-dependent endpoints, such as PFS and the time to
tumor progression (TTP), have been increasingly used in
clinical trials (12), and recent data from nearly 600 patients
with CRPC suggest that PSA progression is able to predict
OS in CRPC (25). Of note, PSA levels are not independent
predictors of OS in CRPC when other clinical or laboratory
parameters are considered (34).
Several chemotherapeutic agents, such as the anthracy-
clines, alkylating agents, antimetabolites, platinums, and
topoisomerase inhibitors, have been assessed in numerous
phase II clinical trials over the years (26,27). In a review of 26
different drugs before the PSA era, the average response
rate was only 8.7%, but the combination of vinblastine plus
estramustine was regarded as promising (27). This combi-
nation was assessed in randomized trials, but the results at
the time did not establish a reference regimen, and toxicity
remained a concern in the setting of palliative therapy for
typically elderly men (35,36). In combination, both mitox-
antrone and low-dose prednisone had displayed modest
single-agent activity and good tolerability in phase II clinical
trials (37,38). In randomized trials, mitoxantrone and a
corticosteroid relieved pain and improved the quality of life
more frequently than with the same corticosteroid alone (39-
41). Therefore, before the advent of docetaxel, mitoxantrone
eventually became the reference chemotherapeutic agent for
the treatment of patients with CRPC (24). However, this
approach was not associated with gain in OS (approxi-
mately 12 months) or gains in quality of life, and improved
regimens were sought.
Docetaxel as the standard of care in the first-line
treatment of CRPC
After the demonstration of its single-agent activity (42,43),
docetaxel was assessed in two phase III clinical trials
published in 2004 (24,44). In the first study, 1,006 patients
with CRPC were randomized to receive mitoxantrone
(12 mg/m2 every three weeks), docetaxel (75 mg/m2 every
three weeks), or weekly docetaxel (30 mg/m2), all combined
with prednisone (5 mg twice daily) (24). As the primary
endpoint of the study, OS improved in both docetaxel arms
compared to mitoxantrone; however, these improvements
were statistically significant when docetaxel was adminis-
tered every three weeks (hazard ratio [HR] = 0.76; p= 0.009),
but not weekly (HR = 0.91; p= 0.36). The median OS times
were 16.5 months with mitoxantrone, 18.9 months with
docetaxel every three weeks, and 17.4 months with weekly
docetaxel. The secondary endpoints of predefined reduc-
tions in pain (22% vs. 35% vs. 31%), PSA response (32% vs.
45% vs. 48%), and improvements in quality of life (13% vs.
22% vs. 23%) were all significantly superior for both
docetaxel schedules. However, docetaxel led to more
adverse events than mitoxantrone – mainly neutropenia.
In the second study, 674 eligible patients with CRPC were
randomized to receive estramustine (280 mg three times
daily on days 1 through 5), docetaxel (60 mg/m2 on day 2),
and dexamethasone (in three divided doses before doc-
etaxel), or mitoxantrone (12 mg/m2) plus prednisone (5 mg
of twice daily), both regimens given every three weeks (44).
The median OS, the primary endpoint, was longer with
docetaxel and estramustine than with mitoxantrone (17.5
months vs. 15.6 months; HR = 0.80; p= 0.02). Likewise, the
TTP (median of 6.3 months vs. 3.2 months) and decline in
PSA (50% vs. 27%) significantly favored the docetaxel-
containing regimen, but it was also more frequently
associated with adverse events. The results of these two
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studies established docetaxel as the new standard agent for
first-line treatment of CRPC, and the toxicity of this agent
was considered acceptable. However, the role of estramus-
tine remained uncertain, and docetaxel every three weeks
plus prednisone was accepted as a reference for future
studies and for clinical practice.
SECOND-LINE TREATMENT OPTIONS FOR CRPC
Cabazitaxel
Cabazitaxel, a novel member of the taxane class of
antimicrotubule agents, demonstrated effectiveness in pre-
clinical models resistant to paclitaxel and docetaxel (45,46).
Furthermore, cabazitaxel is able to cross the blood-brain
barrier, a potential advantage in the treatment of some
malignancies (47). On the basis of phase I and II clinical
trials, the dose of cabazitaxel recommended for future
studies ranged from 20 to 25 mg/m2, and the effects were
observed in docetaxel-refractory prostate cancers and in
other tumors (46,48). Thus, a phase III clinical trial was
launched with the aim of comparing cabazitaxel to
mitoxantrone in docetaxel-refractory CRPC (13). In this
study, 755 patients were treated with prednisone (10 mg
daily) and randomized to receive either cabazitaxel (25 mg/
m2) or mitoxantrone (12 mg/m2) every three weeks, with
OS as the primary endpoint. The median OS was 15.1
months in the cabazitaxel group and 12.7 months in the
mitoxantrone group (HR = 0.70; p,0.0001). Cabazitaxel was
associated with a higher incidence of adverse events than
mitoxantrone. The most common toxicities associated with
cabazitaxel were neutropenia, anemia, and diarrhea. Of
note, peripheral neuropathy was uncommon and typically
mild or moderate in severity (13). The results of this phase
III clinical trial led to the approval of cabazitaxel for the
second-line treatment of CRPC in many countries, including
Brazil. To date, cabazitaxel is the only agent that has been
compared with a chemotherapy control in a phase III
clinical trial in this disease setting. Although not based on
phase III data in the second-line setting, mitoxantrone was
chosen as a control arm in this study due to its frequent use
in the community practice. Recently after the Food and
Drug Administration (FDA) approved cabazitaxel on June
2010, the drug was approved in Brazil by the National
Agency of Health Surveillance (ANVISA) to be adminis-
tered in association with prednisone or prednisolone in the
treatment of docetaxel-refractory metastatic CPRC. In
addition to the United States, cabazitaxel had been
approved for marketing in Israel, Curac¸ao and in the
European Union, along with Iceland, Lichtenstein and
Norway.
Abiraterone
Abiraterone is a selective inhibitor of androgen biosynth-
esis through its action on cytochrome P450 17 (17a-
hydroxylase-17,20-lyase), the key enzyme in androgen and
estrogen biosynthesis (49). Based on the evidence that CRPC
remains sensitive to androgens derived from the adrenal
gland or by endocrine synthesis, preclinical studies have
suggested that abiraterone is effective in CRPC (19).
Moreover, a phase I/II clinical trial has found a PSA
response in nearly two-thirds of the 42 patients with
chemotherapy-naı¨ve CRPC (50). In a phase III trial,
abiraterone (1000 mg/day) was compared to placebo, both
combined with prednisone (5 mg twice daily), in 1196
patients with docetaxel-refractory metastatic CRPP (51). The
primary OS endpoint was significantly different between
the two groups: there was a 35% reduction in the risk of
death (HR = 0.65; p,0.0001) and a median OS of 14.8 months
with abiraterone vs. 10.9 months with placebo. Secondary
efficacy endpoints, such as PFS, TTP, and PSA responses,
consistently favored the abiraterone group, and the toxi-
cities of this agent were primarily hypokalemia and fluid
retention. Based on the results of this study, the FDA
approved abiraterone in combination with prednisone as a
treatment for docetaxel-refractory metastatic CPRC patients
in April 2011.
Sipuleucel-T
Immunological mechanisms likely influence the behavior
of prostate cancer and other malignancies. Sipuleucel-T, a
type of therapeutic cancer vaccine, is able to elicit active
immunologic cellular responses by autologous peripheral-
blood mononuclear cells that have been activated ex vivo
with a recombinant fusion protein consisting of prostatic
acid phosphatase and the immune-cell activator granulo-
cyte–macrophage colony-stimulating factor (14). The use of
sipuleucel-T involves harvesting peripheral blood mono-
nuclear cells from the patient, culturing them with the
fusion protein, and then infusing the antigen-presenting
cells back into the patient. The combined analysis of two
relatively small randomized trials have shown that sipu-
leucel-T produced a survival benefit in 225 patients with
CRPC compared to those treated with placebo; it had an
acceptable toxicity profile consisting mostly of chills, fever,
and headache (52). Thus, a third placebo-controlled phase
III clinical trial was launched, and 512 patients were
randomized in a 2:1 ratio to receive sipuleucel-T or placebo
intravenously every two weeks for a total of three infusions
(14). The study revealed a 22% relative reduction in the risk
of death with the use of sipuleucel-T (HR = 0.78; p= 0.03),
which represented a 4.1-month improvement in the median
OS (25.8 months vs. 21.7 months in the placebo group).
However, the TTP was similar in the two study groups; this
relatively uncommon finding in medical oncology (i.e.,
survival prolongation with no accompanying delay in
tumor progression) has been identified as surprising and
worthy of further investigation, likely related to the
mechanism of action of the vaccine, which could change
the natural history of disease progression (52). Nevertheless,
sipuleucel-T has been approved by the FDA for the
treatment of patients with asymptomatic or minimally
symptomatic CRPC.
OTHER AGENTS
Novel antitumor therapies
Several novel agents are currently being investigated for
the treatment of patients with CRPC (19). MDV3100 is an
androgen-receptor antagonist with no agonistic activity that
allows for the exploitation of the continued reliance on
androgen-receptor signaling by CRPC. In a phase I/II
clinical trial conducted in the United States, antitumor
activity was noted at all dosage levels with a PSA response
in 56% of 140 patients with CRPC (53). Such promising
results have prompted the continued development of this
agent in larger trials. Bevacizumab, the anti-vascular
endothelial growth factor antibody, has been added to
standard docetaxel therapies but has not been shown to
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improve the OS in patients with CRPC, despite an
improvement in PFS; it was also associated with a higher
morbidity and mortality than docetaxel alone in a large
phase III clinical trial published in abstract form (54).
Bone-targeting agents
There are several potential explanations for the marked
predisposition of prostate cancer to metastasize preferen-
tially to bones (55). Both osteoblasts and osteoclasts appear
to play a critical role in the interactions between prostate
cancer cells and bone, and the receptor activator of nuclear
factor kappa-B ligand (RANKL) is a key element in
osteoclastogenesis, bone resorption, and chemoattraction
of tumor cells (56). The prominent role of bone metastases in
the natural history of metastatic prostate cancer has
prompted investigators to target this site of metastasis in
hopes of palliating symptoms and prolonging survival
through the use of androgen ablation, bisphosphonates,
radiopharmaceuticals, focal radiation, chemotherapy, and
targeted agents (55). Successful results from these efforts
have included the demonstration that zoledronic acid
reduces the rate of skeletal-related events in patients with
CRPC (57) and that radiopharmaceuticals may have a role
as a consolidation therapy in patients treated with anti-
tumor agents (58). More recently, targeting RANKL with the
monoclonal antibody denosumab has been found to be
more efficacious than treatment with zoledronic acid in
terms of skeletal-related events in patients with CRPC, as
observed by a significant delay in the time to first and
subsequent on-study skeletal-related events (HR 0.82;
p= 0.004) compared to zoledronic acid. Additionally, the
median time to the first on-study skeletal-related event was
20.7 months for the denosumab group compared with 17.1
months for the zoledronic acid group (59).
Bone-seeking agents
Although the use of bone-seeking radiopharmaceuticals is
currently approved for the palliation of bone pain, a
randomized phase II study using sequential ketoconazole
plus doxorubicin and strontium-89 showed a prolonged
survival (16.8 to 27.7 months) compared to chemotherapy
alone (58). More recently, a phase I study evaluated the
effect of samarium-153 ethylenediamine tetramethylene-
phosphonate (153Sm-EDTMP) administered repetitively in
a docetaxel chemotherapy regimen in patients with castra-
tion-resistant metastatic prostate cancer (60). The results
from this study demonstrated that this combination led to a
greater than 50% decline in prostate-specific antigen with-
out significant bone marrow toxicity.
Endothelin receptor antagonists
The endothelin pathway has been implicated in promot-
ing osteoblastic activity, a feature of bone metastases in
prostate cancer (61). Two selective endothelin-A antagonists
have been evaluated in this population: atrasentan and
zibotentan. Data from a study in 809 CRPC patients
demonstrated that atrasentan (10 mg/day) did not reduce
the TTP compared to placebo, although a significant
decrease in the molecular markers of disease progression
was observed. The same result for the TTP was observed
with zibotentan, despite the improvement in OS, in a phase
II clinical trial. These preliminary findings highlight the
need for further evaluation in this group of patients.
Calcitriol
There is no consensus among clinical oncologists on the
utility of calcitriol in the treatment of CRPC, although
preclinical data have demonstrated it has potent antitumor
activity with antiproliferative, antiangiogenic, and apopto-
sis-induction effects. Calcitriol also appears to synergisti-
cally act with dexamethasone.
In 2010, Chadha et al. (62) published the results of a phase
II clinical trial using intravenous calcitriol and dexametha-
sone in patients with CRPC. The results from this study
indicated that this combination did not produce a clinical or
PSA response. More recently, a phase III study evaluated
the efficacy of docetaxel plus high-dose calcitriol compared
to docetaxel plus prednisone (ASCENT 2) in 953 patients
with CRPC; it reported a higher number of deaths, shorter
overall survival and shorter duration of treatment in the
ASCENT arm compared to the control arm. These findings
led to the termination of the trial, and the clinical
development of the formulation of calcitriol used in this
study was discontinued (63,64).
CONCLUSIONS
The introduction of docetaxel in 2004 began a new era in
the management of CRPC. Over the past few years,
additional progress has been made in the development of
novel agents with activity against docetaxel-refractory
disease and with the potential to improve docetaxel-based
first-line therapies in the near future. At present, cabazitaxel
is the only agent that has been compared to a chemotherapy
control in a phase III clinical trial in patients with docetaxel-
refractory CRPC, and sipuleucel-T is available in some
countries for asymptomatic patients. Abiraterone appears to
be a new treatment option for docetaxel-refractory CPRC
patients. Over the next few years, results from studies on
these and other novel agents will likely increase the
therapeutic arsenal used to treat CRPC.
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